CN1671418A - 降钙素的口服施用 - Google Patents

降钙素的口服施用 Download PDF

Info

Publication number
CN1671418A
CN1671418A CNA038182955A CN03818295A CN1671418A CN 1671418 A CN1671418 A CN 1671418A CN A038182955 A CNA038182955 A CN A038182955A CN 03818295 A CN03818295 A CN 03818295A CN 1671418 A CN1671418 A CN 1671418A
Authority
CN
China
Prior art keywords
calcitonin
oral
amount
disodium salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038182955A
Other languages
English (en)
Chinese (zh)
Inventor
M·阿兹里亚
S·D·贝特曼
J·F·麦克劳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1671418A publication Critical patent/CN1671418A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA038182955A 2002-08-01 2003-07-31 降钙素的口服施用 Pending CN1671418A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40013902P 2002-08-01 2002-08-01
US60/400,139 2002-08-01

Publications (1)

Publication Number Publication Date
CN1671418A true CN1671418A (zh) 2005-09-21

Family

ID=31495795

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038182955A Pending CN1671418A (zh) 2002-08-01 2003-07-31 降钙素的口服施用

Country Status (19)

Country Link
US (2) US20060135402A1 (enExample)
EP (1) EP1526871A1 (enExample)
JP (4) JP2005535689A (enExample)
KR (6) KR20130004389A (enExample)
CN (1) CN1671418A (enExample)
AR (1) AR040737A1 (enExample)
AU (1) AU2003260346B2 (enExample)
BR (1) BR0313177A (enExample)
CA (1) CA2494212A1 (enExample)
IL (1) IL166337A (enExample)
MX (1) MXPA05001266A (enExample)
NO (1) NO20051023L (enExample)
NZ (1) NZ537944A (enExample)
PE (1) PE20040724A1 (enExample)
PL (1) PL373143A1 (enExample)
RU (1) RU2355417C2 (enExample)
TW (1) TWI307279B (enExample)
WO (1) WO2004012772A1 (enExample)
ZA (1) ZA200500516B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
CN104961687A (zh) * 2015-06-03 2015-10-07 苏州维泰生物技术有限公司 1,2-二嗪衍生物及其制剂、用途
CN107050433A (zh) * 2007-03-02 2017-08-18 诺华股份有限公司 降钙素的口服施用
CN113694190A (zh) * 2015-02-09 2021-11-26 安特拉贝欧有限公司 骨质疏松症的治疗
US12239691B2 (en) 2016-08-17 2025-03-04 Entera Bio Ltd. Formulations for oral administration of active agents

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101627011A (zh) 2005-09-19 2010-01-13 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
PT2460515T (pt) * 2007-08-09 2017-04-27 Novartis Ag Composições orais de calcitonina e suas aplicações
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US20110039930A1 (en) * 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
IL307875A (en) 2021-04-22 2023-12-01 Civi Biopharma Inc Oral administration of oligonucleotides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
DE60017888T2 (de) * 1999-04-05 2006-01-19 Emisphere Technologies, Inc. Dinatrium-salze, monohydrate und ethanol-solvate
WO2000059480A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Lyophilized solid dosage forms and methods of making
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107050433A (zh) * 2007-03-02 2017-08-18 诺华股份有限公司 降钙素的口服施用
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
CN113694190A (zh) * 2015-02-09 2021-11-26 安特拉贝欧有限公司 骨质疏松症的治疗
CN113713090A (zh) * 2015-02-09 2021-11-30 安特拉贝欧有限公司 骨质疏松症的治疗
CN113694190B (zh) * 2015-02-09 2024-05-07 安特拉贝欧有限公司 骨质疏松症的治疗
US12076373B2 (en) 2015-02-09 2024-09-03 Entera Bio Ltd. Formulations for oral administration of active agents
CN104961687A (zh) * 2015-06-03 2015-10-07 苏州维泰生物技术有限公司 1,2-二嗪衍生物及其制剂、用途
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
US12239691B2 (en) 2016-08-17 2025-03-04 Entera Bio Ltd. Formulations for oral administration of active agents

Also Published As

Publication number Publication date
NZ537944A (en) 2006-11-30
TWI307279B (en) 2009-03-11
JP2016056190A (ja) 2016-04-21
KR20050032101A (ko) 2005-04-06
AR040737A1 (es) 2005-04-20
EP1526871A1 (en) 2005-05-04
US20060135402A1 (en) 2006-06-22
AU2003260346B2 (en) 2007-12-13
TW200408409A (en) 2004-06-01
US20070232524A1 (en) 2007-10-04
JP2005535689A (ja) 2005-11-24
JP2011026348A (ja) 2011-02-10
RU2005105691A (ru) 2006-01-20
KR20170097232A (ko) 2017-08-25
RU2355417C2 (ru) 2009-05-20
ZA200500516B (en) 2006-07-26
US7569539B2 (en) 2009-08-04
IL166337A (en) 2011-10-31
KR20140084354A (ko) 2014-07-04
KR20130004389A (ko) 2013-01-09
JP5941035B2 (ja) 2016-06-29
BR0313177A (pt) 2005-06-14
KR20160113319A (ko) 2016-09-28
IL166337A0 (en) 2006-01-16
PL373143A1 (en) 2005-08-22
JP2014062112A (ja) 2014-04-10
WO2004012772A1 (en) 2004-02-12
MXPA05001266A (es) 2005-04-28
CA2494212A1 (en) 2004-02-12
NO20051023L (no) 2005-04-27
AU2003260346A1 (en) 2004-02-23
KR20110014690A (ko) 2011-02-11
PE20040724A1 (es) 2004-12-06

Similar Documents

Publication Publication Date Title
CN1304048C (zh) 用于口服递送药理学活性剂的药物组合物
JP5941035B2 (ja) カルシトニンの経口投与
CN101621991A (zh) 降钙素的口服施用
AU2002234547A1 (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CN1809377B (zh) 包含微粉化形式的传送剂的口服给药药物组合物
AU2005202705B2 (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication